| abstract |
This invention relates to genetic markers of mental illness, e.g., schizophrenia (SZ), and methods of use thereof. In particular, in vitro methods of predicting a human subject's likely response to treatment with quetiapine, perphenazine, or ziprasidone, or of selecting a treatment for schizophrenia comprising administration of quetiapine, perphenazine, or ziprasidone, comprising detecting a haplotype comprising one or more polymorphic markers in AKAP13 or markers in linkage disequilibrium (LD) therewith, are provided. |